Aziyo is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. From our proprietary tissue processing platforms, we have developed a portfolio of advanced regenerative medical products that are designed to be very similar to natural biological material.
Nasdaq:
Data Provided by Refinitiv.
Minimum 15 minutes delayed.
Last updated 12/21/2020 3:20 AM EST.
Aziyo Investor Relations.
Nasdaq:
Data Provided by Refinitiv.
Minimum 15 minutes delayed.
Last updated 12/21/2020 3:20 AM EST.
Aziyo is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. From our proprietary tissue processing platforms, we have developed a portfolio of advanced regenerative medical products that are designed to be very similar to natural biological material.
Commercial launch of ViBone ® Moldable, a next generation moldable cellular bone matrix product in the US. DEERFIELD, Ill., January 12, 2021 — Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on advancing spine surgery including through the application of digital...
SILVER SPRING, Md., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for...
SILVER SPRING, Md., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will...